AstraZeneca says new facility in Dublin on target for 2026 completion

Confirmation comes as company plans to invest $50bn in the US over the next five years

Drug maker AstraZeneca has announced plans to invest $50bn (€42.6bn) in the US over the next five years amid the looming threat of US president Donald Trump's trade tariffs.

Drug maker AstraZeneca has announced plans to invest $50bn (€42.6bn) in the US over the next five years amid the looming threat of US president Donald Trump's trade tariffs.

The firm said the investment will fund a new "state-of-the-art" manufacturing facility in Virginia - set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas.